Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer

Prostate Cancer and Prostatic Diseases volume 11, pages 153–159 (2008)Cite this article

Abstract

Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Schelhammer PF, Sharifi R, Block N, Soloway MS, Venner PM, Patterson AL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advance prostatic carcinoma: final repot of a double blind randomized multicenter trial. Urology 1997; 50: 330–336.

    Article  Google Scholar 

  2. Schellhammer PF . An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opin Pharmacother 2002; 3: 1313–1328.

    Article  CAS  PubMed  Google Scholar 

  3. Jenkins V, Fallowfield L, Edginton T, Payne H, Hamilton E . Preferences of healthy men for two different endocrine treatment options offered for locally advanced prostate cancer. Curr Med Res Opinion 2005; 21: 1329–1335.

    Article  CAS  Google Scholar 

  4. Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M . Patients’ preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ 2004; 328: 382.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Louviere J, Hensher D, Swait JD, Adamowicz W . Stated Choice Methods: Analysis and Applications. Cambridge University Press: Cambridge, UK, 2000.

    Book  Google Scholar 

  6. Ryan M, Farrar S . Using conjoint analysis to elicit preferences in health care. BMJ 2000; 320: 1530–1533.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Osman LM, McKenzie L, Cairns J, Friend JAR, Godden DJ, Legge JS et al. Patient weighting of importance of asthma symptoms. Thorax 2001; 56: 138–142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lloyd A, McIntosh E, Price M . The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment. Pharmacoeconomics 2005; 23: 1167–1181.

    Article  CAS  PubMed  Google Scholar 

  9. Denis LJ, Keuppens F, Smith PH, Whelan P, Carneiro de Moura JL, Newling D et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998; 33: 144–151.

    Article  CAS  PubMed  Google Scholar 

  10. Hedlund PO . Side effects of endocrine treatment and their mechanisms: castration, antiandrogens and estrogens. Prostate 2000; 10: 32–37.

    Article  CAS  Google Scholar 

  11. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of randomised trials. Lancet 2000; 355: 1491–1498.

    Article  Google Scholar 

  12. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036–1042.

    Article  CAS  PubMed  Google Scholar 

  13. Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F et al., for the International Prostate Cancer Study Group. Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Cancer 1993; 72: 3878–3879.

    Article  CAS  PubMed  Google Scholar 

  14. Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer: the Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 1993; 29A: 1088–1093.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge the support and scientific insight from Mr Joe Crawley and Mr Sanjay Gandhi, Astra Zeneca. This research was supported by AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Author information

Authors and Affiliations

  1. United BioSource Corporation, London, UK

    A Lloyd

  2. Departments of Urology and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    D Penson

  3. United BioSource Corporation, Brussels, Belgium

    S Dewilde

  4. United BioSource Corporation, Seattle, WA, USA

    L Kleinman

Authors
  1. A Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Penson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Dewilde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Kleinman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Lloyd.

Additional information

Declaration

Professor Penson has undertaken consultancy work for Astra-Zeneca, Dendreon and Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lloyd, A., Penson, D., Dewilde, S. et al. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 11, 153–159 (2008). https://doi.org/10.1038/sj.pcan.4500992

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500992

Keywords

This article is cited by

Search

Advanced search

Quick links